Clinical Trials Logo

Clinical Trial Summary

This study develops a prospective database of patients who are evaluated and treated for penile cancer. This will facilitate analyzing trends in cancer incidence, risk factors, treatment, complications, and tumor progression. It will also prospectively validate the importance of pathological prognostic factors previously reported and outcome related to contemporary treatment.


Clinical Trial Description

PRIMARY OBJECTIVE: I. To prospectively collect data on the presenting features, management and outcome of penile carcinoma at M.D. Anderson Cancer Center, and Harris Health System and Katy, Sugar Land, The Woodlands and Bay Area Regional Care Centers. OUTLINE: Patients undergo data collection every 6 months for up to 15 years. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04996849
Study type Observational
Source M.D. Anderson Cancer Center
Contact
Status Recruiting
Phase
Start date April 22, 2004
Completion date December 31, 2026

See also
  Status Clinical Trial Phase
Recruiting NCT02104063 - Characterising Metastatic Penile Cancer Using Molecular Imaging - Hybrid MRI-PET [MRI-PET] N/A
Not yet recruiting NCT06161532 - Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as Small Cell, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile Cancer Phase 2
Completed NCT03517488 - A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors Phase 1
Withdrawn NCT02014831 - Efficacy and Safety of Cetuximab in Metastatic Penile Carcinoma (PENILANE) Phase 2
Recruiting NCT03221400 - PEN-866 in Patients With Advanced Solid Malignancies Phase 1/Phase 2